Freeline Therapeutics(FRLN) - 2022 Q4 - Annual Report

Exhibit 99.1 Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update Prioritizing development of FLT201, a potential first- and best-in-class gene therapy for most common type of Gaucher disease Initial clinical data on FLT201 expected in Q3 2023 Restructuring organization and pausing development of FLT190 to extend cash runway into Q2 2024 Appointed CFO Paul Schneider to Board of Directors Management to host conference call today at 8 a.m. ET LONDON, April 4, 2023 – Freeline Therape ...